ORIGINAL RESEARCH article

Front. Immunol.

Sec. Cancer Immunity and Immunotherapy

Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1581850

This article is part of the Research TopicNeural influences on tumor immunity: Exploring neuroimmunology in cancerView all 4 articles

Molecular Insights into Glioblastoma Progression: Role of CHCHD2P9 in Tumor Heterogeneity and Prognosis

Provisionally accepted
Yanyu DingYanyu Ding1,2lizhi xiaolizhi xiao2jiaxin zhaojiaxin zhao2jianli kejianli ke2huabao caihuabao cai2Mengyu ZhaoMengyu Zhao2cunzhi wangcunzhi wang2Tian-Hang YuTian-Hang Yu2Zhijie ZhaoZhijie Zhao2yucai wangyucai wang1,2jiyuan kejiyuan ke2*
  • 1University of Science and Technology of China, Hefei, China
  • 2Anhui Medical University, Hefei, Anhui Province, China

The final, formatted version of the article will be published soon.

Select one of your emails

You have multiple emails registered with Frontiers:

Notify me on publication

Please enter your email address:

If you already have an account, please login

You don't have a Frontiers account ? You can register here

Background: Gliomas are highly aggressive, life-threatening tumors with poor prognosis, and remain a leading cause of mortality among brain cancers. Although the role of mitochondrial proteins in cancer has garnered increasing attention, their specific functions in the nervous system, particularly in gliomas, remain poorly understood.We integrated single-cell RNA sequencing with cellular assays and flow cytometry to investigate the molecular characteristics and cellular interactions within glioblastoma subpopulations during tumor progression.Results: Single-cell RNA sequencing revealed several differentially expressed genes (DEGs) within glioblastoma subpopulations. Trajectory analysis identified CHCHD2P9 as a pivotal marker for the terminal subpopulation. Moreover, elevated expression of CHCHD2P9 was found to correlate with poorer clinical outcomes. Subsequent cellular experiments further explored the underlying mechanisms driving these observations. Conclusions: CHCHD2P9 is significantly overexpressed in glioma patients, and its differential expression plays a crucial role in regulating glioma cell proliferation and migration. A CHCHD2P9based risk model holds promise as both a prognostic biomarker and a potential therapeutic target, providing novel insights into the pathogenesis of gliomas and opening avenues for personalized treatment strategies.

Keywords: Glioblastoma, CHCHD2P9, diagnosis, prognosis, Central Nervous System, tumor microenvironment 2.2 Data Standardization and Quality Control

Received: 23 Feb 2025; Accepted: 06 Jun 2025.

Copyright: © 2025 Ding, xiao, zhao, ke, cai, Zhao, wang, Yu, Zhao, wang and ke. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: jiyuan ke, Anhui Medical University, Hefei, 230032, Anhui Province, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Supplementary Material